type: misc

label: url

en: Triple-negative breast cancer and basal-like subtype : Pathology and targeted therapy.

en: Triple-negative breast cancer (TNBC) is a heterogenous disease. For personalized medicine, it is essential to identify and classify tumor subtypes to develop effective therapeutic strategies. Although gene expression profiling has identified several TNBC subtypes, classification of these tumors remains complex. Most TNBCs exhibit an aggressive phenotype, but some rare types have a favorable clinical course. In this review, we summarize the classification and characteristics related to the various TNBC subtypes, including the rare types. Therapeutic methods that are suitable for each subtype are also discussed. Of the intrinsic breast cancer subtypes identified by gene expression analysis, the basal-like subtype specifically displayed decreased expression of an estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2) cluster. We also present results that characterize the TNBC and basal-like phenotypes. TNBC may be categorized into four major classes : basal-like, immune-enriched, mesenchymal, and luminal androgen receptor. Therapeutic strategies for each subtype have been proposed along with newly approved targeted therapies for TNBC, such as immune checkpoint inhibitors. Understanding the classification of TNBC based on gene expression profiling in association with clinicopathological factors will facilitate accurate pathological diagnosis and effective treatment selection. J. Med. Invest. 68 : 213-219, August, 2021.

en: The Journal of Medical Investigation : JMI


en: [画像診断と病理] 石灰化腱膜上皮種

ja: [画像診断と病理] 石灰化腱膜上皮種

en: 画像診断

ja: 画像診断


en: [画像診断と病理] 胎盤分葉状解離性平滑筋腫

ja: [画像診断と病理] 胎盤分葉状解離性平滑筋腫


en: [画像診断と病理] 尿膜管癌(粘液性腺癌)

ja: [画像診断と病理] 尿膜管癌(粘液性腺癌)


en: Sinonasal-type hemangiopericytomaの1例

ja: Sinonasal-type hemangiopericytomaの1例

en: 診断病理

ja: 診断病理


en: FAKシグナルの肺線維化における役割-ブレオマイシン肺線維症モデルでの検討

ja: FAKシグナルの肺線維化における役割-ブレオマイシン肺線維症モデルでの検討

en: Respiratory Molecular Medicine

ja: 分子呼吸器病


en: Angiogenesis of prostate cancer and antiangiogenic therapy

en: Tumor-associated angiogenesis refers to the growth of new vessels toward and within the tumor. Several studies have revealed that increasing intratumoral microvessel density, a major of tumor-associated angiogenesis, correlates with greater aggressiveness of prostate cancer. Angiogenesis consists of multiple, sequential, and interdependent steps dependent on the local balance of proangiogenic and antiangiogenic molecules Many proangiogenic and antiangiogenic molecules have been demonstrated to regulate growth and metastasis of prostate cancer. As tumor-associated angiogenesis is a crucial step in the process of prostate cancer development, inhibition of tumor neovascularization, and/or destruction of tumor vasculature (antiangiogenic therapy) may maintain the tumors in a dormant state or, perhaps in combination with cytotoxic therapies, potentiate shrinkage of tumors. Recently, therapeutic agents targeting the receptors of proangiogenic molecules and their signal transduction cascade have been developed. In this article, the role of angiogenic molecules in prostate cancer biology, and the application of angiogenesis inhibition to therapeutics for prostate cancer are reviewed.

ja: The Journal of Medical Investigation : JMI


en: ブレイオマイシン誘発肺線維症モデルにおける分子標的治療薬Imatinib(Gleevec)の抗線維化効果

en: 厚生省特定疾患 特発性間質性肺炎の画期的治療法による臨床研究報告書

ja: 厚生省特定疾患 特発性間質性肺炎の画期的治療法による臨床研究報告書

misc_type: others


en: ブレオマイシン誘発肺線維症モデルにおける分子標的治療薬Imatinib(Gleevec)の抗線維化効果

en: 厚生科学研究 特定疾患対策研究事業 びまん性肺疾患研究班 平成15年度報告書

ja: 厚生科学研究 特定疾患対策研究事業 びまん性肺疾患研究班 平成15年度報告書